Gastric Adenocarcinoma Clinical Trials

56 recruiting

Gastric Adenocarcinoma Trials at a Glance

88 actively recruiting trials for gastric adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 42 trials, with the heaviest enrollment activity in New York, Houston, and Dallas. Lead sponsors running gastric adenocarcinoma studies include Memorial Sloan Kettering Cancer Center, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and M.D. Anderson Cancer Center.

Browse gastric adenocarcinoma trials by phase

Treatments under study

About Gastric Adenocarcinoma Clinical Trials

Looking for clinical trials for Gastric Adenocarcinoma? There are currently 56 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 88 trials

Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled370 locationsNCT06203600
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 2

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

Gastric Adenocarcinoma
Banner Health30 enrolled1 locationNCT07178808
Recruiting
Phase 1Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast CancerEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma+1 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 3

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled224 locationsNCT06901531
Recruiting
Phase 2

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Stomach NeoplasmsGastric Adenocarcinoma
Jinbo Yue54 enrolled1 locationNCT07007182
Recruiting
Phase 2

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Metastatic Gastric AdenocarcinomaAdvanced Esophageal AdenocarcinomaAdvanced Gastric Adenocarcinoma+1 more
UNICANCER88 enrolled4 locationsNCT06846346
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 3

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
BeOne Medicines351 enrolled85 locationsNCT07043400
Recruiting
Phase 2

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Esophageal AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Weill Medical College of Cornell University27 enrolled2 locationsNCT06340711
Recruiting
Phase 1

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled45 locationsNCT05365581
Recruiting
Phase 2

Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

Gastric AdenocarcinomaEsophagogastric Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences70 enrolled1 locationNCT06761846
Recruiting
Phase 2

Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ

Gastric AdenocarcinomaGastro-esophageal Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences61 enrolled1 locationNCT06808971
Recruiting
Phase 1Phase 2

Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer

Advanced Gastroesophageal Junction AdenocarcinomaAdvanced Gastric Adenocarcinoma
Beijing Biotech36 enrolled1 locationNCT07551362
Recruiting
Phase 2

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Stage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Gastric Adenocarcinoma+2 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03161522
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorEsophageal Squamous Cell CarcinomaGastric Adenocarcinoma+2 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology382 enrolled791 locationsNCT05677490
Recruiting
Phase 1Phase 2

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

ChemotherapyMetastatic Gastric AdenocarcinomaSecond Line
National Health Research Institutes, Taiwan45 enrolled1 locationNCT05927857
Recruiting
Phase 2

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Gastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaMetastatic Malignant Neoplasm in the Peritoneum
Mayo Clinic40 enrolled1 locationNCT05753306
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Gastric AdenocarcinomaBladder CancerMesothelioma+7 more
IDEAYA Biosciences260 enrolled10 locationsNCT07277413